Skip to main content
Premium Trial:

Request an Annual Quote

It's Not That Simple

Thanks to a new test, checking for genetic abnormalities in a fetus is easier and less invasive — but there's a downside, says Nature News' Erika Check Hayden. Sequenom's new MaterniT21 Down syndrome test requires only a small sample of the mother's blood, and is only one of several similar tests expected to hit the market soon, Hayden says. While such tests spare women from amniocentesis or other invasive procedures, doctors say they pose other problems, Hayden says. "For instance, because it would take 8-10 days to get the results of Sequenom's test, if a woman did still opt for amniocentesis, and the result confirms that the baby has Down's syndrome, there would be little time left to decide whether to terminate the pregnancy," she adds. "And some women who test positive on MaterniT21 will probably choose to terminate pregnancies immediately rather than have amniocentesis." Ethicists are also concerned, saying easy screening methods could cause a worse gender imbalance, or could cause parents to face difficult decisions about whether to carry the pregnancy to term. "Other ethicists worry that fears of eugenics will be raised if testing can be done for less-serious conditions," Hayden adds.

Daily Scan sister publication Clinical Sequencing News has more on the MaterniT21 test here and here.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.